HUMAM W FARAH
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
- Where
- Hannibal, MO
- NPI
- 1306880141
- Received
- $840,262 in 1,468 records, 2019 to 2025 ($840,112 general, $150 research)
- As principal investigator
- $1,902,133 of research payments to others in 368 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 250 | $140,947 |
| 2024 | General payment | 261 | $97,931 |
| 2023 | General payment | 288 | $198,041 |
| 2022 | General payment | 228 | $155,529 |
| 2021 | General payment | 153 | $86,725 |
| 2021 | Research payment | 1 | $150 |
| 2020 | General payment | 88 | $42,654 |
| 2019 | General payment | 199 | $118,282 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 253 | $635,744 |
| Travel and Lodging | 432 | $106,604 |
| Honoraria | 11 | $51,000 |
| Food and Beverage | 749 | $29,230 |
| Consulting Fee | 18 | $17,188 |
| Education | 4 | $344 |
| Research payment | 1 | $150 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | HARMONY BIOSCIENCES LLC | $25 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-12-16 | Viatris Specialty LLC | $18 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-12-11 | Verona Pharma, Inc. | $5,000 | Honoraria | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-12-11 | Verona Pharma, Inc. | $487 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-12-11 | Verona Pharma, Inc. | $434 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-12-11 | Verona Pharma, Inc. | $327 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-12-11 | Verona Pharma, Inc. | $121 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-12-10 | Verona Pharma, Inc. | $12 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-12-09 | HARMONY BIOSCIENCES LLC | $65 | Education | In-kind items and services | 2025 | ||
| 2025-12-09 | Boston Scientific Corporation | $23 | Food and Beverage | In-kind items and services | WATCHMAN Access System Device, WATCHMAN_IC | 2025 | |
| 2025-12-09 | HARMONY BIOSCIENCES LLC | $15 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-12-03 | Takeda Pharmaceuticals U.S.A., Inc. | $1,485 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-03 | Viatris Specialty LLC | $17 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-11-20 | Philips North America LLC | $37 | Food and Beverage | Cash or cash equivalent | Vest Therapy Und Device, Medical Device | 2025 | |
| 2025-11-19 | Verona Pharma, Inc. | $24 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-11-18 | Viatris Specialty LLC | $1,769 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-11-18 | AstraZeneca Pharmaceuticals LP | $950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-18 | Viatris Specialty LLC | $18 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-11-17 | Takeda Pharmaceuticals U.S.A., Inc. | $1,485 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-13 | Takeda Pharmaceuticals U.S.A., Inc. | $657 | Travel and Lodging | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2025 | |
| 2025-11-13 | Grifols USA, LLC | $19 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-11-13 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | AREXVY Biological, RESPIRATORY | 2025 | |
| 2025-11-13 | HARMONY BIOSCIENCES LLC | $14 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-11-12 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-11 | Insmed, Inc. | $19 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-11-06 | Verona Pharma, Inc. | $21 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-11-05 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-11-03 | Viatris Specialty LLC | $27 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-10-31 | Takeda Pharmaceuticals U.S.A., Inc. | $154 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-31 | Takeda Pharmaceuticals U.S.A., Inc. | $50 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-30 | Verona Pharma, Inc. | $5,000 | Honoraria | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-10-30 | Verona Pharma, Inc. | $549 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-10-30 | Verona Pharma, Inc. | $331 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-10-30 | Verona Pharma, Inc. | $124 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-10-28 | Takeda Pharmaceuticals U.S.A., Inc. | $5,643 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-28 | Verona Pharma, Inc. | $7 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-10-23 | Avadel CNS Pharmaceuticals, LLC | $24 | Food and Beverage | In-kind items and services | LUMRYZ Drug, CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | 2025 | |
| 2025-10-21 | Verona Pharma, Inc. | $24 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-10-16 | HARMONY BIOSCIENCES LLC | $6 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-10-15 | HARMONY BIOSCIENCES LLC | $24 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-10-14 | AstraZeneca Pharmaceuticals LP | $140 | Travel and Lodging | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-10-14 | AstraZeneca Pharmaceuticals LP | $66 | Travel and Lodging | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-10-14 | Actelion Pharmaceuticals US, Inc. | $25 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-10-14 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-10-11 | AstraZeneca Pharmaceuticals LP | $1,860 | Consulting Fee | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-10-10 | AstraZeneca Pharmaceuticals LP | $1,860 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-10 | AstraZeneca Pharmaceuticals LP | $1,860 | Consulting Fee | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-10-09 | Insmed, Inc. | $18 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-10-08 | Takeda Pharmaceuticals U.S.A., Inc. | $674 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-08 | Takeda Pharmaceuticals U.S.A., Inc. | $487 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-08 | Takeda Pharmaceuticals U.S.A., Inc. | $332 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-08 | Takeda Pharmaceuticals U.S.A., Inc. | $25 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-07 | Verona Pharma, Inc. | $13 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-10-06 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-10-01 | AstraZeneca Pharmaceuticals LP | $1,242 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-10-01 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-30 | Viatris Specialty LLC | $2,527 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-09-30 | Viatris Specialty LLC | $71 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-09-30 | Viatris Specialty LLC | $30 | Travel and Lodging | Cash or cash equivalent | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-09-29 | Viatris Specialty LLC | $113 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-09-29 | Viatris Specialty LLC | $3 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-09-25 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-09-24 | Verona Pharma, Inc. | $5,000 | Honoraria | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-09-24 | Verona Pharma, Inc. | $2,314 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-09-24 | Verona Pharma, Inc. | $111 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-09-22 | HARMONY BIOSCIENCES LLC | $10 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-09-19 | Takeda Pharmaceuticals U.S.A., Inc. | $17 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-09-19 | Takeda Pharmaceuticals U.S.A., Inc. | $11 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-09-16 | Verona Pharma, Inc. | $2,500 | Honoraria | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-09-16 | Verona Pharma, Inc. | $124 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-09-16 | Itamar Medical Inc | $26 | Food and Beverage | Cash or cash equivalent | WatchPATONE Device, Sleep Apnea testing | 2025 | |
| 2025-09-15 | Verona Pharma, Inc. | $10 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $295 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $283 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $135 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $63 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $57 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $54 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $40 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-11 | Verona Pharma, Inc. | $5,000 | Honoraria | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-09-11 | Verona Pharma, Inc. | $411 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-09-11 | Verona Pharma, Inc. | $292 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-09-11 | Verona Pharma, Inc. | $156 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-09-11 | Verona Pharma, Inc. | $111 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-09-11 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-09-10 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-09 | Viatris Specialty LLC | $14 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-09-05 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-04 | AstraZeneca Pharmaceuticals LP | $1,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-02 | Insmed, Inc. | $16 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-08-29 | HARMONY BIOSCIENCES LLC | $20 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-08-27 | Verona Pharma, Inc. | $5,000 | Honoraria | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-08-27 | Verona Pharma, Inc. | $409 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-08-27 | Verona Pharma, Inc. | $371 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-08-27 | Verona Pharma, Inc. | $301 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-08-27 | Verona Pharma, Inc. | $124 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-08-25 | Esperion Therapeutics, Inc. | $14 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-08-21 | AstraZeneca Pharmaceuticals LP | $92 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-08-21 | AstraZeneca Pharmaceuticals LP | $19 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-08-14 | HARMONY BIOSCIENCES LLC | $30 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-08-12 | Viatris Specialty LLC | $22 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-08-12 | Verona Pharma, Inc. | $13 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-08-06 | Takeda Pharmaceuticals U.S.A., Inc. | $23 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2025 | |
| 2025-08-06 | Takeda Pharmaceuticals U.S.A., Inc. | $9 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-08-05 | HARMONY BIOSCIENCES LLC | $20 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-08-05 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-07-31 | United Therapeutics Corporation | $109 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-07-30 | Viatris Specialty LLC | $12 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-07-29 | Insmed, Inc. | $21 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-07-29 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2025 | |
| 2025-07-29 | Verona Pharma, Inc. | $12 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-07-25 | AstraZeneca Pharmaceuticals LP | $950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-07-24 | Verona Pharma, Inc. | $5,000 | Honoraria | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-07-24 | Verona Pharma, Inc. | $428 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-07-24 | Verona Pharma, Inc. | $381 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-07-24 | Verona Pharma, Inc. | $250 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-07-24 | Verona Pharma, Inc. | $114 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-07-22 | Lilly USA, LLC | $22 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-17 | Actelion Pharmaceuticals US, Inc. | $22 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-07-17 | Actelion Pharmaceuticals US, Inc. | $5 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-07-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-14 | Verona Pharma, Inc. | $8 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-07-10 | Takeda Pharmaceuticals U.S.A., Inc. | $19 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2025 | |
| 2025-07-10 | Takeda Pharmaceuticals U.S.A., Inc. | $10 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2025 | |
| 2025-07-10 | HARMONY BIOSCIENCES LLC | $7 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-07-09 | Viatris Specialty LLC | $2,321 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-07-09 | Viatris Specialty LLC | $113 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-07-09 | Viatris Specialty LLC | $38 | Travel and Lodging | Cash or cash equivalent | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-07-08 | JAZZ PHARMACEUTICALS INC. | $18 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-06-26 | Baxter Healthcare | $14 | Food and Beverage | In-kind items and services | Hillrom - Monarch Airway Clearance System Device, Airway Clearance Device | 2025 | |
| 2025-06-20 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Adempas Drug, Cardio-pulmonary | 2025 | |
| 2025-06-18 | HARMONY BIOSCIENCES LLC | $90 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-06-17 | Insmed, Inc. | $15 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-05-29 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-05-29 | Viatris Specialty LLC | $7 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-05-27 | Takeda Pharmaceuticals U.S.A., Inc. | $23 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-05-27 | Takeda Pharmaceuticals U.S.A., Inc. | $10 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-05-21 | Verona Pharma, Inc. | $14 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-05-20 | Vifor Pharma, Inc. | $25 | Food and Beverage | In-kind items and services | Zemaira Biological, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-05-20 | Exact Sciences Corporation | $13 | Food and Beverage | In-kind items and services | The Cologuard Plus Collection Kit Device, Oncology | 2025 | |
| 2025-05-15 | ANI Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 | |
| 2025-05-15 | Takeda Pharmaceuticals U.S.A., Inc. | $10 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-13 | Viatris Specialty LLC | $16 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-05-08 | Verona Pharma, Inc. | $5,000 | Honoraria | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-05-08 | Verona Pharma, Inc. | $478 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-05-08 | Verona Pharma, Inc. | $397 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-05-08 | Verona Pharma, Inc. | $257 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-05-08 | Verona Pharma, Inc. | $118 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-05-07 | Merck Sharp & Dohme LLC | $13 | Food and Beverage | In-kind items and services | GARDASIL 9 Biological, VACCINE | 2025 | |
| 2025-05-06 | Takeda Pharmaceuticals U.S.A., Inc. | $29 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-05-06 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-05-02 | AstraZeneca Pharmaceuticals LP | $1,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-05-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-01 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-29 | Actelion Pharmaceuticals US, Inc. | $17 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-04-29 | Verona Pharma, Inc. | $6 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-04-25 | AstraZeneca Pharmaceuticals LP | $2,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-04-24 | Verona Pharma, Inc. | $5,000 | Honoraria | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-04-24 | Verona Pharma, Inc. | $454 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-04-24 | Verona Pharma, Inc. | $286 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-04-24 | Verona Pharma, Inc. | $267 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-04-24 | Verona Pharma, Inc. | $118 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-04-24 | Verona Pharma, Inc. | $45 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-04-23 | Verona Pharma, Inc. | $15 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-04-17 | HARMONY BIOSCIENCES LLC | $16 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-04-17 | HARMONY BIOSCIENCES LLC | $1 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-04-15 | Actelion Pharmaceuticals US, Inc. | $88 | Education | In-kind items and services | OPSUMIT Drug, Cardiology | 2025 | |
| 2025-04-15 | JAZZ PHARMACEUTICALS INC. | $19 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-04-10 | Takeda Pharmaceuticals U.S.A., Inc. | $21 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2025 | |
| 2025-04-10 | Takeda Pharmaceuticals U.S.A., Inc. | $9 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2025 | |
| 2025-04-10 | Takeda Pharmaceuticals U.S.A., Inc. | $3 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2025 | |
| 2025-04-09 | Viatris Specialty LLC | $1,702 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-04-09 | AstraZeneca Pharmaceuticals LP | $108 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-04-09 | AstraZeneca Pharmaceuticals LP | $89 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-04-09 | Viatris Specialty LLC | $22 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-04-08 | ANI Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 | |
| 2025-04-08 | Verona Pharma, Inc. | $12 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-04-03 | Merck Sharp & Dohme LLC | $20 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-04-01 | Insmed, Inc. | $18 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-04-01 | Viatris Specialty LLC | $5 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-03-27 | Verona Pharma, Inc. | $5,000 | Honoraria | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-03-27 | Verona Pharma, Inc. | $3,500 | Honoraria | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-03-27 | Verona Pharma, Inc. | $493 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-03-27 | Verona Pharma, Inc. | $275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-03-27 | Verona Pharma, Inc. | $275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-03-27 | Verona Pharma, Inc. | $224 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-03-27 | Verona Pharma, Inc. | $202 | Travel and Lodging | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-03-27 | Verona Pharma, Inc. | $95 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-03-26 | Verona Pharma, Inc. | $7 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-03-25 | Baxter Healthcare | $18 | Food and Beverage | In-kind items and services | Hillrom - Vest System Model 105 Home Care Device, Airway Clearance Device | 2025 | |
| 2025-03-20 | Actelion Pharmaceuticals US, Inc. | $19 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-03-19 | Bayer Healthcare Pharmaceuticals Inc. | $17 | Food and Beverage | In-kind items and services | Adempas Drug, Cardio-pulmonary | 2025 | |
| 2025-03-13 | HARMONY BIOSCIENCES LLC | $16 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-03-11 | Takeda Pharmaceuticals U.S.A., Inc. | $19 | Food and Beverage | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2025 | |
| 2025-03-11 | Takeda Pharmaceuticals U.S.A., Inc. | $14 | Food and Beverage | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2025 | |
| 2025-03-10 | Verona Pharma, Inc. | $9 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-03-06 | AstraZeneca Pharmaceuticals LP | $92 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-06 | ANI Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 |
The latest 200 records of 1,468.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-22 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $1,032 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-12-17 | Genentech, Inc. | ELLIGO HEALTH RESEARCH INC | $1,313 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-12-17 | Genentech, Inc. | ELLIGO HEALTH RESEARCH INC | $1,801 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-12-17 | Genentech, Inc. | ELLIGO HEALTH RESEARCH INC | $1,313 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-12-16 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $450 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-12-16 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $375 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-12-16 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $458 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-12-11 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $375 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-12-11 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $675 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-12-11 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $585 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-12-11 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $396 | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 |
| 2025-12-08 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $2,300 | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | 2025 |
| 2025-12-02 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $350 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-11-21 | Genentech, Inc. | ELLIGO HEALTH RESEARCH INC | $788 | Ph IIb of Astegolimab in COPD | 2025 |
| 2025-11-19 | Genentech, Inc. | ELLIGO HEALTH RESEARCH INC | $77 | Ph IIb of Astegolimab in COPD | 2025 |
| 2025-11-18 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $5,866 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2025 |
| 2025-11-12 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $2,600 | Roche Cancer Screening Collection Study | 2025 |
| 2025-11-07 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $1,100 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-11-07 | AstraZeneca Pharmaceuticals LP | HANNIBAL REGIONAL HEALTHCARE SYSTEM, INC | $21,313 | Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Sa | 2025 |
| 2025-11-07 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $800 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-11-07 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $600 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-11-04 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $1,500 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-10-27 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $18,608 | A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and saf | 2025 |
| 2025-10-21 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $2,763 | Ph III OLE of Astegolimab in COPD | 2025 |
| 2025-10-14 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $3,881 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-10-14 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $1,500 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2025 |
| 2025-10-14 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $2,556 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2025 |
| 2025-10-14 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $1,000 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2025 |
| 2025-10-14 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $3,153 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2025 |
| 2025-10-14 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $1,008 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2025 |
| 2025-10-08 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $3,000 | Roche Cancer Screening Collection Study | 2025 |
| 2025-10-06 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $1,050 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-10-06 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $3,217 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-10-06 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $1,400 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-10-02 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $1,926 | Ph III OLE of Astegolimab in COPD | 2025 |
| 2025-09-25 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $2,571 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-09-25 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $13,300 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-09-25 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $13,300 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-09-25 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $3,019 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-09-25 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $3,019 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-09-25 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $448 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-09-24 | AstraZeneca Pharmaceuticals LP | Elligo Health Research, Inc | $427 | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Effi | 2025 |
| 2025-09-15 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $1,655 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-09-11 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $7,395 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2025 |
| 2025-09-02 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $1,926 | Ph III OLE of Astegolimab in COPD | 2025 |
| 2025-08-21 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $10,567 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2025 |
| 2025-08-14 | Merck Sharp & Dohme LLC | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $1,031 | A Test-Negative Case-Control Study to Evaluate the Effectiveness of V116 Against Pneumococcal Pneumonia in Older Adults | 2025 |
| 2025-08-05 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $18,190 | Ph III OLE of Astegolimab in COPD | 2025 |
| 2025-07-31 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $13,300 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-07-31 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $3,019 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-07-31 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $448 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-07-21 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $600 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-07-14 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $4,205 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-07-04 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $6,435 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-07-02 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $3,258 | Roche Cancer Screening Collection Study | 2025 |
| 2025-06-04 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $1,584 | Roche Cancer Screening Collection Study | 2025 |
| 2025-05-28 | Genentech, Inc. | ELLIGO HEALTH RESEARCH INC | $1,180 | Ph IIb of Astegolimab in COPD | 2025 |
| 2025-05-28 | Genentech, Inc. | ELLIGO HEALTH RESEARCH INC | $2,100 | Ph IIb of Astegolimab in COPD | 2025 |
| 2025-05-28 | Genentech, Inc. | ELLIGO HEALTH RESEARCH INC | $325 | Ph IIb of Astegolimab in COPD | 2025 |
| 2025-05-27 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $309 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2025 |
| 2025-05-27 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $750 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2025 |
| 2025-05-27 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $30,734 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2025 |
| 2025-05-15 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $2,571 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-05-15 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $448 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-05-15 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $3,019 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-05-14 | Merck Sharp & Dohme LLC | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $6,847 | A Test-Negative Case-Control Study to Evaluate the Effectiveness of V116 Against Pneumococcal Pneumonia in Older Adults | 2025 |
| 2025-05-13 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $1,000 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2025 |
| 2025-05-06 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $23,024 | Ph III OLE of Astegolimab in COPD | 2025 |
| 2025-05-05 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $4,887 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-04-22 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE S | $9,032 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2025 |
| 2025-04-14 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $18,600 | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | 2025 |
| 2025-04-09 | Genentech, Inc. | ELLIGO HEALTH RESEARCH INC | $2,758 | Ph IIb of Astegolimab in COPD | 2025 |
| 2025-04-07 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $26,600 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-04-07 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $6,038 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-04-07 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $1,550 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-04-07 | SANOFI US SERVICES INC. | Vantage Clinical Trials Llc | $7,426 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-04-07 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $400 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-04-07 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $448 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-04-07 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $2,571 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-04-04 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $8,341 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-04-02 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $3,463 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-03-21 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $792 | Roche Cancer Screening Collection Study | 2025 |
| 2025-03-17 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $20,000 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-03-12 | VERTEX PHARMACEUTICALS INCORPORATED | BLESSING CORPORATE SERVICES INC. DBA BLESSING HEALTH SYSTEM | $5,465 | Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype | 2025 |
| 2025-03-03 | Genentech, Inc. | ELLIGO HEALTH RESEARCH INC | $1,905 | Ph IIb of Astegolimab in COPD | 2025 |
| 2025-02-28 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $1,584 | Roche Cancer Screening Collection Study | 2025 |
| 2025-02-18 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $3,948 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-02-12 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $792 | Roche Cancer Screening Collection Study | 2025 |
| 2025-02-06 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $36,333 | Ph III OLE of Astegolimab in COPD | 2025 |
| 2025-01-31 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $792 | Roche Cancer Screening Collection Study | 2025 |
| 2025-01-21 | SANOFI US SERVICES INC. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $2,688 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-01-17 | Genentech, Inc. | ELLIGO HEALTH RESEARCH INC | $1,180 | Ph IIb of Astegolimab in COPD | 2025 |
| 2025-01-17 | Genentech, Inc. | ELLIGO HEALTH RESEARCH INC | $1,300 | Ph IIb of Astegolimab in COPD | 2025 |
| 2025-01-13 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $2,376 | Roche Cancer Screening Collection Study | 2025 |
| 2025-01-09 | United Therapeutics Corporation | Hannibal Regional Healthcare System | $4,528 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | Elligo Health Research, Inc | $1,621 | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Effi | 2024 |
| 2024-12-13 | Merck Sharp & Dohme LLC | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $24,196 | A Test-Negative Case-Control Study to Evaluate the Effectiveness of V116 Against Pneumococcal Pneumonia in Older Adults | 2024 |
| 2024-12-13 | Merck Sharp & Dohme LLC | Hannibal Regional Healthcare System Inc. | $24,196 | STUDY NAME# Pilot for a Test-Negative Case-Control Study to Evaluate the Effectiveness of a New Adult Pneumococcal Vacci | 2024 |
| 2024-12-10 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $987 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2024 |
| 2024-12-10 | Genentech, Inc. | HANNIBAL REGIONAL HEALTHCARE SYSTEM INC | $375 | Phase 2 Double Blind Randomized Study in IPF and SSc ILD | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Hannibal, MO, county Marion County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Hannibal, MO | County Marion County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 16,771 | 28,457 | 6,191,814 |
| Population, 2020 census P1 | 17,108 | 28,525 | 6,154,913 |
| Median age B01002 | 38.5 | 39.6 | 39.0 |
| Under 18 B01001 | 23.2% | 24.0% | 22.3% |
| 65 and over B01001 | 19.7% | 19.0% | 17.9% |
| Households B11001 | 6,891 | 11,323 | 2,508,227 |
| Foreign born B05002 | 0.6% | 0.6% | 4.5% |
| Median household income B19013 | $53,721 | $62,903 | $70,702 |
| Median family income B19113 | $62,304 | $76,314 | $91,360 |
| Per capita income B19301 | $26,203 | $30,271 | $39,695 |
| Poverty rate B17001 | 19.5% | 14.2% | 12.6% |
| Unemployment rate B23025 | 5.2% | 3.8% | 4.0% |
| Civilian labor force B23025 | 7,279 | 13,092 | 3,120,639 |
| Mean commute (minutes) B08013 | 15.3 | 17.6 | 23.5 |
| Bachelor's degree or higher B15003 | 19.5% | 24.6% | 32.4% |
| Housing units B25001 | 7,835 | 12,917 | 2,825,287 |
| Owner-occupied B25003 | 62.2% | 69.3% | 68.1% |
| Renters B25003 | 37.8% | 30.7% | 31.9% |
| Median home value B25077 | $127,700 | $162,000 | $230,300 |
| Median gross rent B25064 | $805 | $808 | $1,033 |
| White, not Hispanic B03002 | 87.3% | 89.0% | 76.3% |
| Black B03002 | 5.7% | 4.2% | 10.9% |
| Hispanic or Latino B03002 | 2.7% | 2.0% | 5.2% |
| Asian B03002 | 1.1% | 0.8% | 2.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Hannibal, MO.
Comments